中证报中证网讯(记者李梦扬)7月18日，国家药品监督管理局官网显示，抗流感1类创新药济可舒(通用 名：玛硒洛沙韦片)获批上市。 据介绍，济可舒是我国自主研发、具有全球自主知识产权的新一代靶向流感病毒RNA聚合酶PA抑制 剂，通过特异性抑制病毒mRNA的转录发挥抗病毒作用。研究显示，济可舒的临床研究对象均源于中国 患者，临床用药依据更具针对性和适用性，契合国人体质特点，为抗击流感提供治疗方案。 据了解，济可舒治疗青少年无并发症的单纯性流感Ⅲ期临床研究已经递交上市申请(NDA)，5岁-11岁儿 童无并发症单纯性流感的有效性及安全性等多项Ⅲ期临床研究正在开展，以满足患者差异化用药需求。 随着流感季的常态化，高效、安全、便捷的治疗方案成为临床与患者的共同需求。公司称，济可舒有望 为流感患者提供差异化用药选择，为抗击流感贡献了中国智慧，也为全球抗流感药物市场注入了新的活 力。 据悉，济川药业（600566）与征祥医药于2023年围绕济可舒注册、生产、推广、渠道管理及商业销售达 成战略合作，济川药业享有济可舒在中国的独家推广和销售权益。 由国家传染病医学中心、复旦大学附属华山医院感染科主任张文宏教授，中国医学科学院北京协 ...

Group 1 - Chinese assets are experiencing a resurgence, with NIO and Li Auto rising nearly 7% as foreign investment increases in A-shares [2] - The Invesco Global Sovereign Asset Management Research indicates a noticeable recovery in interest from international investment institutions towards the Chinese market, managing approximately $27 trillion in assets [2] - Several foreign institutions express optimism about Chinese assets due to the stable economic performance, policy benefits, and improved corporate earnings outlook [2] Group 2 - The U.S. House of Representatives has advanced cryptocurrency legislation, supported by President Trump, which has led to significant stock price increases for companies in the crypto sector [3] - Blue Ocean Interactive surged over 45% after announcing the establishment of LK Crypto, focusing on mainstream crypto asset management and RWA [3] - Hong Kong is actively developing stablecoin products, creating a dual regulatory framework that connects the U.S. dollar stablecoin with the mainland [3] Group 3 - The Hong Kong IPO market is witnessing a surge, with a significant increase in financing amounts, reflecting global capital's confidence in China's industrial upgrade and consumption potential [7] - On July 9, the Hong Kong Stock Exchange saw five companies queueing for listing in a single day, raising over 10 billion HKD [7] Group 4 - The domestic consumption and investment policies are being emphasized by the Chinese government to strengthen the domestic circulation [5][6] - Analysts highlight the urgency and necessity of promoting consumption as a core strategy for economic growth [6] Group 5 - The A-share market has seen an increase in financing balance for eight consecutive days, totaling an increase of 44.038 billion CNY, indicating positive market sentiment [10] - Analysts suggest that the current macro environment and market risk appetite signal potential for further market growth [10] Group 6 - The number of private equity MOM products registered this year has reached a new high, with 43 products registered by July 15, surpassing the total for the past nine years [14] - This trend indicates a strong interest in the MOM fund model, which allows for diversified asset management [14] Group 7 - The beverage brand Wahaha is facing a decline in sales following a family dispute involving its chairman, which has raised concerns among distributors [16] - The internal family conflict could potentially disrupt the competitive landscape of the Chinese beverage industry [16] Group 8 - The domestic electric vehicle market is seeing significant growth, with L2-level assisted driving penetration exceeding 50% [18] - The heavy truck sales in the first half of the year have increased by approximately 7%, with new energy heavy trucks being a major highlight [18] Group 9 - The stock market is experiencing fluctuations, with the Shanghai Composite Index slightly declining by 0.03% to 3503.78 points [19] - The Hong Kong market is also showing mixed performance, with the Hang Seng Index and the Hang Seng Tech Index experiencing slight declines and gains, respectively [19] Group 10 - The U.S. stock market has seen gains driven by positive economic data and corporate earnings reports, with the S&P 500 rising by 0.45% [20] - Approximately 88% of S&P 500 companies that have reported earnings exceeded analyst expectations, boosting investor confidence [20] Group 11 - Several foreign investment banks have expressed positive views on the Chinese market, with Citigroup raising its ratings for Chinese and Korean markets to "overweight" [21] - Citigroup projects the Hang Seng Index to reach 25,000 points by the end of the year and the CSI 300 Index to reach 4,200 points [21] Group 12 - The stock market's investment logic is shifting towards cash flow analysis in a low-interest-rate environment, with a focus on high-dividend and strong cash flow companies [22] - Analysts are optimistic about sectors such as automotive, electronics, and traditional high-growth areas like AI and pharmaceuticals [22]

| 605162 新中港 | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=605162&announcementId=122411 | | --- | --- | | 603928 兴业股份 | 8829&orgId=9900039948&announcementTime=2025 -07-10 https://www.cninfo.com.cn/new/disclosure/detail?stockCode=603928&announcementId=122409 | | | 0364&orgId=9900023749&announcementTime=2025 -07-08 | | 300649 杭州园林 | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=300649&announcementId=122408 9739&orgId=9900023811&announcementTime=2025 -07-07 | | 600571 信雅达 | https://www ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 证券代码：600566 证券简称：济川药业 公告编号：2025-054 湖北济川药业股份有限公司 关于曹飞先生要约收购期满暨股票停牌的公告 因湖北济川药业股份有限公司要约收购事项（以下简称"公司"或"济川药业"）, 本公司的相关证券停复牌情况如下： 特此公告。 湖北济川药业股份有限公司董事会 2025 年 7 月 18 日 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生向除曹龙祥先生、江苏济川控股集团有限公司及西藏济川企业管理 有限公司以外的济川药业全体持有无限售条件流通股的股东发出全面要约。本次 要约收购股份数量为 350,841,357 股，占公司总股本的 38.06%，要约收购价格为 24.85 元/股（鉴于公司 2024 年年度利润分配方案已实施完毕，本次要约收购的要 约收购价格由 26.93 元/股调整为 24.85 元/股）,要约收购期限为 2025 年 6 月 18 日至 20 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-053 湖北济川药业股份有限公司 关于全资子公司开立募集资金现金管理专用结算账户 并利用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 委托现金管理受托方：渤海银行股份有限公司泰州分行(以下简称"渤海 银行泰州分行")、东方财富证券股份有限公司(以下简称"东方财富") 履行的审议程序：湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十届董事会第十四次会议和第十届监事会第十四次会议， 于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于全资子公司 利用闲置募集资金和自有资金进行现金管理的议案》，同意公司在不影响募投项 目正常实施并保证募集资金安全的前提下，使用额度不超过 5.8 亿元（含本数） 的闲置募集资金进行现金管理，投资对象为安全性高、流动性好、有保本约定、 投资期限不超过 12 个月的投资产品，包括但不限于理财产品、结构性存款、定 期存 ...

New Stock Issuance - Shanda Electric (Stock Code: 301609) issued at a price of 14.66[1] - Jiyuan Group (Stock Code: 732262) issued at a price of 10.88[1] Market Alerts - Jichuan Pharmaceutical (Stock Code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - The last trading day for Tuisan Jinguang (Stock Code: 600190) is July 14, 2025, with 4 trading days remaining[1] - The last trading day for Tuisan Jinjing (Stock Code: 900952) is also July 14, 2025, with 4 trading days remaining[1] Abnormal Fluctuations - *ST Zitian (Stock Code: 300280) reported severe abnormal fluctuations on July 10, 2025[1] - *ST Yushun (Stock Code: 002289) reported abnormal fluctuations on July 11, 2025[1] Other Notable Announcements - Longyuan Green Energy (Stock Code: 603185) announced on July 11, 2025[1] - Kedi Pharmaceutical (Stock Code: 000590) announced on July 14, 2025[1]

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

New Stock Offerings - Ji Chuan Pharmaceutical (600566) is in the offer period from June 18, 2025, to July 17, 2025[1] - Zhong Cheng Tui (300208) has 5 trading days remaining until the last trading day[1] - Tui Shi Jin Gang (600190) also has 5 trading days remaining until the last trading day[1] Delisting and Trading Alerts - Hengli Tui (000622) has 2 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has only 1 trading day remaining until the last trading day[1] - ST Zi Tian (300280) has an announcement dated July 10, 2025, regarding trading status[1] Abnormal Fluctuations - Changcheng Military Industry (601606) reported severe abnormal fluctuations on July 2, 2025[1] - An abnormal fluctuation was noted for Wei Xin Kang (603676) on July 5, 2025[2] - Multiple stocks, including ST Wei Ming (002581), reported abnormal fluctuations on July 11, 2025[2]

Summary of Key Points Core Viewpoint - The announcement details Mr. Cao Fei's offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a total of 350,841,357 shares being targeted for acquisition at a revised price of 24.85 yuan per share, down from 26.93 yuan per share [1][2]. Group 1: Offer Details - The offer is triggered as Mr. Cao Fei, through Jichuan Holdings and Tibet Jichuan Enterprise Management Co., Ltd., holds 56.07% of the company's shares, exceeding the 30% threshold that mandates a public offer [2]. - The offer period is set for 30 calendar days, starting from June 18, 2025, to July 17, 2025, with specific trading days where shareholders cannot withdraw their acceptance of the offer [2][4]. - The payment method for the acquisition is cash, and the offer is not intended to terminate the listing status of Jichuan Pharmaceutical [2][4]. Group 2: Acceptance and Withdrawal Procedures - Shareholders wishing to accept the offer must submit their applications through their designated securities companies during the offer period, with the effective number of shares based on their actual holdings [3]. - If shareholders wish to withdraw their acceptance, they must do so at least three trading days before the offer period ends, and the shares will be temporarily held by China Securities Shanghai Branch during this time [3][5]. - The company will provide updates on the progress of the offer and the number of shares accepted [2][4]. Group 3: Offer Statistics - As of July 10, 2025, a total of 4,100 shares have been accepted under the offer, representing approximately 0.0004% of the company's total share capital [5][6]. - The company will issue a separate announcement regarding the results of the offer and any subsequent clearing announcements after the offer period concludes [5][6].